» Articles » PMID: 11488332

Quality of Life of Idiopathic Pulmonary Fibrosis Patients

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2001 Aug 8
PMID 11488332
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Little attention has been paid to quality of life (QOL) in idiopathic pulmonary fibrosis (IPF). Therefore, the aim of this study was to address this issue and study the relationship between QOL, depressive symptoms, and breathlessness in these patients. Forty-one IPF patients and 41 healthy persons matched for age and sex completed the World Health Organization Quality of Life assessment instrument-100. The IPF patients also completed the Beck Depression Inventory, the Bath Breathlessness Scale, a social support questionnaire and a question concerning perceived seriousness of illness. Compared to the control group, QOL in IPF patients was mainly impaired in the domains "physical health" and "level of independence". A number of relationships were found between pulmonary function tests and QOL. The QOL facet "negative feelings" was highly associated with scores on depression. Subjective breathlessness was related to depressive symptoms and QOL. Moreover, sex and effective/emotional breathlessness predicted overall QOL. In conclusion, the impairment of the quality of life areas "physical health" and "level of independence" are important issues in idiopathic pulmonary fibrosis. Subjective breathlessness, especially the effective/emotional scale, seems related to quality of life and depressive symptoms. Rehabilitation programmes are needed that are aimed at physiological aspects and psychosocial aspects of idiopathic pulmonary fibrosis in order to enhance the quality of life of these patients.

Citing Articles

Health-related quality of life and health state utility value in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.

Zhao G, Lei S, Li Y, Feng Z, Li J Health Qual Life Outcomes. 2025; 23(1):3.

PMID: 39757157 PMC: 11702038. DOI: 10.1186/s12955-024-02326-y.


Neurocognitive and Neuropsychiatric Implications of Fibrosing Interstitial Lung Diseases.

Vastag Z, Tudorache E, Traila D, Fira-Mladinescu O, Marc M, Oancea C Biomedicines. 2024; 12(11).

PMID: 39595138 PMC: 11591599. DOI: 10.3390/biomedicines12112572.


Assessment of quality of life in IPF Patients: a multicenter observational study.

Uzer F, Cilli A, Hanta I, Coskun F, Sevinc C, Ursavas A Sarcoidosis Vasc Diffuse Lung Dis. 2024; 41(3):e2024043.

PMID: 39315976 PMC: 11472669. DOI: 10.36141/svdld.v41i3.15805.


Can FDG-PET/CT imaging be used to predict decline in quality of life in interstitial lung disease? A prospective study of the relationship between FDG uptake and quality of life in a UK outpatient setting.

Jordon L, Ganeshan B, Nadeem I, Hoy L, Mahdi N, Porter J BMJ Open. 2024; 14(5):e081103.

PMID: 38816048 PMC: 11141197. DOI: 10.1136/bmjopen-2023-081103.


Palliative care and end of life management in patients with idiopathic pulmonary fibrosis.

Micco A, Carpentieri E, Di Sorbo A, Chetta A, Del Donno M Multidiscip Respir Med. 2023; 18:896.

PMID: 36909932 PMC: 9994447. DOI: 10.4081/mrm.2023.896.